Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Keystone State Herald.
Press releases published on June 16, 2025
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Blue Ridge Bankshares, Inc. (NYSE: BRBS); Manhattan Associates, Inc. (NASDAQ: MANH); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
GlobeNewswire
·
June 16, 2025
PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- Blue Ridge Bankshares, Inc. (NYSE: BRBS): If you are a current Blue Ridge Bankshares, Inc. (NYSE: BRBS) shareholder who purchased Blue Ridge shares prior to February 3, 2023, you can seek corporate reforms, …
Barrack, Rodos & Bacine Reminds Shareholders that They Have Less than One Month to Seek Appointment As Lead Plaintiff in the Securities Class Action Lawsuit Against Compass Group Diversified Holdings LLC (CODI)
GlobeNewswire
·
June 16, 2025
PHILADELPHIA, June 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Barrack, Rodos …
A. Duie Pyle Expands Northeast Footprint with New LTL Facility in West Virginia
GlobeNewswire
·
June 16, 2025
WEST CHESTER, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- A. Duie Pyle (Pyle), a premier, 101-year-old family-owned and operated provider of asset and non-asset-based supply chain solutions, today announces the opening of a new less-than-truckload (LTL) service …
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
GlobeNewswire
·
June 16, 2025
The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other …
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
GlobeNewswire
·
June 16, 2025
MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared …
Helius Medical Technologies, Inc. Announces Claim Authorization by CignaHealth, for its Portable Neuromodulation Stimulator (PoNS®) Device
GlobeNewswire
·
June 16, 2025
- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19 …